Immunosurveillance in human non-viral cancers

Current Opinion in Immunology

Volumn 23, Issue 2, 2011, Pages 272-278

  Fridman, Wolf Herman ^a,b,c   Mlecnik, Bernard ^a,b   Bindea, Gabriela ^a,b   Pagès, Franck ^a,b,c   Galon, Jérôme ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERLEUKIN 2; VASCULOTROPIN;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COLORECTAL CANCER; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; GENE EXPRESSION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LUNG CARCINOMA; MELANOMA; MEMORY T LYMPHOCYTE; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; REVIEW; T LYMPHOCYTE; TH1 CELL; TUMOR LOCALIZATION; TUMOR RECURRENCE;

HUMANS; MONITORING, IMMUNOLOGIC; NEOPLASMS; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953076118     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.12.011     Document Type: Review

References (67)

1. Birkeland S.A., Storm H.H., Lamm L.U., Barlow L., Blohme I., Forsberg B., Eklund B., Fjeldborg O., Friedberg M., Frodin L., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995, 60:183-189.
2. Taylor A.L., Marcus R., Bradley J.A. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005, 56:155-167.
3. Camilleri-Broet S., Criniere E., Broet P., Delwail V., Mokhtari K., Moreau A., Kujas M., Raphael M., Iraqi W., Sautes-Fridman C., et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006, 107:190-196.
4. Chang M.H. Hepatitis B vaccination: disease and cancer prevention-a Taiwanese experience. Clin Liver Dis 2010, 14:521-530.
5. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-1868.
6. Harper D.M. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol 2008, 110:S11-17.
7. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
8. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
9. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
10. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
11. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
12. Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006, 90:1-50.
13. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
14. MacKie R.M., Reid R., Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003, 348:567-568.
15. Jass J.R. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986, 39:585-589.
16. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-1102.
17. Bindea G., Mlecnik B., Fridman W.H., Pages F., Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010, 22:215-222.
18. de Visser K.E., Korets L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7:411-423.
19. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
20. Hiraoka N., Onozato K., Kosuge T., Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006, 12:5423-5434.
21. Fu J., Xu D., Liu Z., Shi M., Zhao P., Fu B., Zhang Z., Yang H., Zhang H., Zhou C., et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132:2328-2339.
22. Badoual C., Hans S., Rodriguez J., Peyrard S., Klein C., Agueznay Nel H., Mosseri V., Laccourreye O., Bruneval P., Fridman W.H., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006, 12:465-472.
23. Carreras J., Lopez-Guillermo A., Fox B.C., Colomo L., Martinez A., Roncador G., Montserrat E., Campo E., Banham A.H. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006, 108:2957-2964.
24. Alvaro T., Lejeune M., Salvado M.T., Bosch R., Garcia J.F., Jaen J., Banham A.H., Roncador G., Montalban C., Piris M.A. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005, 11:1467-1473.
25. Salama P., Phillips M., Grieu F., Morris M., Zeps N., Joseph D., Platell C., Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27:186-192.
26. Waldhauer I., Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008, 27:5932-5943.
27. Bindea G., Mlecnik B., Hackl H., Charoentong P., Tosolini M., Kirilovsky A., Fridman W.H., Pages F., Trajanoski Z., Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009, 25:1091-1093.
28. Mlecnik B., Sanchez-Cabo F., Charoentong P., Bindea G., Pages F., Berger A., Galon J., Trajanoski Z. Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. BMC Genomics 2010, 11(Suppl 1):S7.
29. Mlecnik B., Tosolini M., Charoentong P., Kirilovsky A., Bindea G., Berger A., Camus M., Gillard M., Bruneval P., Fridman W.H., et al. Biomolecular network reconstruction identifies T cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138:1429-1440.
30. Pages F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., Lagorce C., Wind P., Marliot F., Bruneval P., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27:5944-5951.
31. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666.
32. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
33. Camus M., Tosolini M., Mlecnik B., Pages F., Kirilovsky A., Berger A., Costes A., Bindea G., Charoentong P., Bruneval P., et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009, 69:2685-2693.
34. Galon J., Fridman W.H., Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007, 67:1883-1886.
35. Fridman W.H., Galon J., Dieu-Nosjean M.C., Cremer I., Fisson S., Damotte D., Pages F., Tartour E., Sautes-Fridman C. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 2010, May 29 (Epub ahead of print).
36. Pages F., Galon J., Fridman W.H. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol 2008, 84:981-987.
37. Masi G., Loupakis F., Salvatore L., Fornaro L., Cremolini C., Cupini S., Ciarlo A., Del Monte F., Cortesi E., Amoroso D., et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010, 11:845-852.
38. Kirkwood J.M., Tarhini A.A. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol 2009, 27:2583-2585.
39. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, et al.: Histopathological-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2010: in press.
40. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., de Chaisemartin L., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008, 26:4410-4417.
41. Baier P.K., Wimmenauer S., Hirsch T., von Specht B.U., von Kleist S., Keller H., Farthmann E.H. Analysis of the T cell receptor variability of tumor-infiltrating lymphocytes in colorectal carcinomas. Tumour Biol 1998, 19:205-212.
42. Diederichsen A.C., Hjelmborg J.B., Christensen P.B., Zeuthen J., Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003, 52:423-428.
43. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58:3491-3494.
44. Pages F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., Lagorce C., Wind P., Marliot F., Bruneval P., et al. The in situ cytotoxic and memory T cells predict outcome in early-stage colorectal cancer patients. J Clin Oncol 2009, 27:1093-1102.
45. Prall F., Duhrkop T., Weirich V., Ostwald C., Lenz P., Nizze H., Barten M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004, 35:808-816.
46. Ropponen K.M., Eskelinen M.J., Lipponen P.K., Alhava E., Kosma V.M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997, 182:318-324.
47. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
48. Mackensen A., Ferradini L., Carcelain G., Triebel F., Faure F., Viel S., Hercend T. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 1993, 53:3569-3573.
49. Tefany F.J., Barnetson R.S., Halliday G.M., McCarthy S.W., McCarthy W.H. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991, 97:197-202.
50. Marrogi A.J., Munshi A., Merogi A.J., Ohadike Y., El-Habashi A., Marrogi O.L., Freeman S.M. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997, 74:492-501.
51. Menegaz R.A., Michelin M.A., Etchebehere R.M., Fernandes P.C., Murta E.F. Per- and intratumoral T and B lymphocytic infiltration in breast cancer. Eur J Gynaecol Oncol 2008, 29:321-326.
52. Sharma P., Shen Y., Wen S., Yamada S., Jungbluth A.A., Gnjatic S., Bajorin D.F., Reuter V.E., Herr H., Old L.J., et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007, 104:3967-3972.
53. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:18538-18543.
54. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
55. Cho Y., Miyamoto M., Kato K., Fukunaga A., Shichinohe T., Kawarada Y., Hida Y., Oshikiri T., Kurokawa T., Suzuoki M., et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003, 63:1555-1559.
56. Schumacher K., Haensch W., Roefzaad C., Schlag P.M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001, 61:3932-3936.
57. Eskelinen M., Lipponen P., Aitto-Oja L., Hall O., Syrjanen K. The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma. Int J Cancer 1993, 55:547-554.
58. Kondo T., Nakazawa H., Ito F., Hashimoto Y., Osaka Y., Futatsuyama K., Toma H., Tanabe K. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006, 97:780-786.
59. Lamb G.W., McArdle P.A., Ramsey S., McNichol A.M., Edwards J., Aitchison M., McMillan D.C. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008, 102:756-761.
60. Li J.F., Chu Y.W., Wang G.M., Zhu T.Y., Rong R.M., Hou J., Xu M. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int 2009, 103:399-405.
61. Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., Suzuki Y., Shintaku I., Nagura H., Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001, 61:5132-5136.
62. Karja V., Aaltomaa S., Lipponen P., Isotalo T., Talja M., Mokka R. Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005, 25:4435-4438.
63. Vesalainen S., Lipponen P., Talja M., Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994, 30A:1797-1803.
64. Al-Shibli K.I., Donnem T., Al-Saad S., Persson M., Bremnes R.M., Busund L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008, 14:5220-5227.
65. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., Itoh T., Ohbuchi T., Kondo S., Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006, 94:275-280.
66. Ito N., Suzuki Y., Taniguchi Y., Ishiguro K., Nakamura H., Ohgi S. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 2005, 25:2027-2031.
67. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., Aokage K., Saijo N., Nishiwaki Y., Gemma A., et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113:1387-1395.